University of Vienna

Complex CRISPR Patent Decision Benefits Broad Institute, Editas

Broad Institute of MIT and Harvard, Business, CRISPR/Cas9, Gene Editing, Medical Journals, Patents, Science, University of Vienna, USPTO

The U.S. Patent and Trademark Office ruled that the use of CRISPR-Cas9 in humans belongs to the Broad Institute of Massachusetts Institute of Technology, not the University of California, Berkeley.

Analysis: Can first Covid-19 vaccines bring herd immunity? Experts have doubts

'Herd Immunity', BioNTech, Coronavirus Disease (COVID-19) Pandemic, Countries, COVID-19 Vaccinations, COVID-19 Vaccines, European Center for Disease Prevention and Control (ECDC), Government, Health Experts, Health Officials, Moderna, Pfizer, Respiratory infections, University of Vienna, World Health Organization

Governments and officials are voicing hopes that Covid-19 vaccines could bring “herd immunity”, with some calculating that immunizing just two-thirds of a population could halt the pandemic disease and help protect whole communities or nations.

USPTO Grants Patent Covering CRISPR/Cas9 Gene Editing

CRISPR/Cas9, DNA, Mammals, Patents, UC Berkeley, Universities, University of California, University of Vienna, USPTO

The U.S. Patent and Trademark Office granted Emmanuelle Charpentier — co-founder of ERS Genomics — the University of California, and the University of Vienna their first U.S. patent covering the use of CRISPR/Cas9 for gene editing.